Arcutis biotherapeutics stock.

Shares of Arcutis Biotherapeutics ( ARQT -3.16%) climbed 21.2% for the week after rising as high as 23.8%, according to data provided by S&P Global Market Intelligence. The medical dermatology ...WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock ...Dec 1, 2023Oct 24, 2023 · After the upgrade, the seven analysts covering Arcutis Biotherapeutics are now predicting revenues of US$44m in 2023. If met, this would reflect a substantial 294% improvement in sales compared to ...

Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.

A Different Perspective. Arcutis Biotherapeutics shareholders may not have made money over the last year, but their total loss of 5.5% isn't as bad as the market loss of around 5.5%.

Get Arcutis Biotherapeutics Inc (ARQT.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.There’s also Arcutis Biotherapeutics (NASDAQ:ARQT), a $217 million immuno-dermatology company, whose moderate-to-severe seborrheic dermatitis treatment will face FDA decision on Dec. 16.Nov 3, 2023 · ARQT stock had a significant performance on November 3, 2023. According to data from CNN Money, eight analysts have offered 12-month price forecasts for Arcutis Biotherapeutics Inc, with a median target of $33.00. The high estimate for the stock price is $50.00, while the low estimate is $4.00. Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Arcutis Biotherapeutics Inc ARQT. Arcutis Biotherapeutics announced the pricing of a $100 million public offering of 32.5 million common shares at $2.50 per share. The company has a 52-week low of ...

These 8 analysts have an average price target of $25.62 versus the current price of Arcutis Biotherapeutics at $2.49, implying upside. Below is a summary of how these 8 analysts rated Arcutis ...

Dec 1, 2023 · 9 analysts have issued twelve-month target prices for Arcutis Biotherapeutics' shares. Their ARQT share price targets range from $6.00 to $57.00. On average, they anticipate the company's stock price to reach $29.67 in the next year. This suggests a possible upside of 1,390.8% from the stock's current price.

May 9, 2023 · ARCUTIS BIOTHERAPEUTICS, INC. Condensed Balance Sheets (In thousands) March 31, December 31, 2023 2022 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 81,405 $ 53,641 Restricted cash 925 1,234 Trade receivable, net 12,769 8,458 Marketable securities 251,000 355,948 Inventories 8,551 A. While ratings are subjective and will change, the latest Arcutis Biotherapeutics ( ARQT) rating was a maintained with a price target of $45.00 to $10.00. The current price Arcutis ...Arcutis Biotherapeutics - ARQT - Stock Price Today - Zacks Arcutis Biotherapeutics (ARQT) (Real Time Quote from BATS) $1.99 USD +0.03 (1.53%) Updated Nov 28, 2023 10:40 AM ET Add to...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Arcutis Biotherapeutics Inc is down 6.97% from its previous closing price of $7.82. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $7.82 and $8.26. Currently, there are 61.43 million shares of Arcutis Biotherapeutics Inc stock available for purchase. Unfortunately, Arcutis Biotherapeutics Inc’s P/E ratio ...Sep 29, 2022 · Arcutis Biotherapeutics' shares are down 15% year to date. Read more to see why ARQT stock is a buy for long-term investors. Arcutis Biotherapeutics' shares are down 15% year to date. Read more to ... Arcutis Biotherapeutics Stock Forecast, ARQT stock price prediction. Price target in 14 days: 2.559 USD. The best long-term & short-term Arcutis ...

On Wednesday, Arcutis Biotherapeutics Inc [NASDAQ: ARQT] plunged -4.59% to $2.08. The stock’s lowest price that day was $2.07, but it reached a high of $2.33 in the same session. During the last five days, there has been a drop of approximately -5.45%. Over the course of the year, Arcutis Biotherapeutics Inc shares have dropped approximately ...Sep 29, 2022 · Arcutis Biotherapeutics' shares are down 15% year to date. Read more to see why ARQT stock is a buy for long-term investors. Arcutis Biotherapeutics' shares are down 15% year to date. Read more to ... Nov 3, 2023 · Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with ... What this means: InvestorsObserver gives Arcutis Biotherapeutics Inc (ARQT) an overall rank of 33, which is below average. Arcutis Biotherapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 33 means that 67% of stocks appear more favorable to our system.According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.Arcutis Biotherapeutics Stock Forecast, ARQT stock price prediction. Price target in 14 days: 2.559 USD. The best long-term & short-term Arcutis ...

Nov 28, 2023 · About Arcutis Biotherapeutics Inc. Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical ... Insider Monkey Transcripts. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) Q4 2022 Earnings Call Transcript February 28, 2023. Operator: Ladies and gentlemen, thank you for standing by. And welcome ...

Best Stocks & ETFs. Best Penny Stocks. Best S&P 500 ETFs. Best Swing Trade Stocks. ... Arcutis Biotherapeutics ARQT is set to give its latest quarterly earnings report on Tuesday, 2023-02-28. Here ...Nov 03, 2023. Report of unscheduled material events or corporate event. 8-K. 0001787306-23-000122.pdf. 0001787306-23-000122.rtf. 0001787306-23-000122.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML. Nov 03, 2023. Quarterly report which provides a continuing view of a company's financial position.Dec 1, 2023 · Arcutis Biotherapeutics last posted its earnings data on November 3rd, 2023. The reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.17. The firm earned $38.11 million during the quarter, compared to the consensus estimate of $9.54 million. Arcutis Biotherapeutics has generated ($4. ... After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT) Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of …Here is how Arcutis Biotherapeutics, Inc. (ARQT) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year. ARQT : (-5.06%) AVEO : The mean of analysts' price targets for Arcutis Biotherapeutics, Inc. (ARQT) points to a 134.2% upside in the stock. While this highly sought-after metric has not proven reasonably ...1.9900. +0.1500. +8.15%. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript November 3, 2023 Arcutis Biotherapeutics, Inc. beats earnings expectations. Reported EPS is ...

The latest price target for Arcutis Biotherapeutics (NASDAQ: ARQT) was reported by Morgan Stanley on Monday, November 13, 2023. The analyst firm set a price ...

Apr 24, 2023 · Arcutis Biotherapeutics (NASDAQ:ARQT) ... It also enacted a public offering of common stock in 2022 where it raised $161.6 million in aggregate net proceeds. Along with the sales of stock under an ...

The Arcutis Biotherapeutics stock prediction for 2025 is currently $ 1.777134, assuming that Arcutis Biotherapeutics shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -12.46% increase in the ARQT stock price.Earlier this month, the company added to its pipeline assets by acquiring privately held Ducentis Biotherapeutics for an upfront cash payment of ~$16 million and Arcutis stock valued at ~$14 ...WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common …Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.Apr 11, 2023 · As of April 11, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $12.89. Arcutis Biotherapeutics Inc is up 4.2% from its previous closing price of $12.37. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $11.83 and $12.47. Currently, there are 61.04 million shares of Arcutis Biotherapeutics ... According to the issued ratings of 9 analysts in the last year, the consensus rating for Arcutis Biotherapeutics stock is Moderate Buy based on the current 3 hold ratings and 6 buy ratings for ARQT. The average twelve-month price prediction for Arcutis Biotherapeutics is $29.67 with a high price target of $57.00 and a low price target of $6.00 ...Mar 18, 2023 · WESTLAKE VILLAGE, Calif., March 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today presented in a late-breaking clinical trial session at the American Academy of Dermatology (AAD) annual meeting (New Orleans, LA ... The stock options have a ten-year term and an exercise price of $1.99 per share, equal to the per share closing price of Arcutis’ common stock as reported by …Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated ...Oct 20, 2023 · Arcutis is selling 32,500,000 shares of common stock and, in lieu of common stock to certain investors, pre-fu. WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics ... NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown.Nov 2, 2023 · That’s why we’re here. Arcutis has a passion for doing and delivering better through innovation. But not just for the sake of innovating—innovation that delivers the results that matter most. The kind that simplifies complex disease management and solves the most persistent challenges of treating chronic inflammatory diseases of the skin.

Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT) Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of …Arcutis Biotherapeutics stock price forecast: $51; Market Cap: 179.32M, Enterprise value: 934.67M, P/E: -2.1, PEG ratio: 0.05, EPS: -4.43, Revenue: 49.04M, ...Instagram:https://instagram. cheap dental plans in floridatuperware stockhigh yeild bondscalculate options profit Mar 18, 2023 · WESTLAKE VILLAGE, Calif., March 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today presented in a late-breaking clinical trial session at the American Academy of Dermatology (AAD) annual meeting (New Orleans, LA ... mortgage companies in delawaredelta air pilot salary See the latest Arcutis Biotherapeutics Inc Ordinary Shares stock price (ARQT:XNAS), related news, valuation, dividends and more to help you make your investing decisions. pff dividend yield Sean Kim PhD, an analyst from JonesTrading, reiterated the Buy rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price target is $44.00. The associated price target is ...Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Before we jump into Arcutis Biotherapeutics Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet ...